|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||62.01 - 62.54|
|52 Week Range||52.83 - 66.41|
|PE Ratio (TTM)||108.54|
|Earnings Date||Jul 27, 2018|
|Forward Dividend & Yield||1.92 (3.09%)|
|1y Target Est||69.44|
Stanley Black & Decker, Microsoft, State Street, Merck and Starbucks are the companies to watch.
Drugmakers have been lining up to tout new drug price policies lately, from deferring increases to freezing drug prices. Merck & Co. Inc. went a step further on Thursday, announcing a cap on average increases and cuts to some drug prices. The largest percentage cut announced was a 60% price reduction for its Zepatier treatment for hepatitis C.
European drugmakers Roche , Bayer and Merck KGaA became the latest companies to freeze prices in the United States for the rest of 2018 following criticism by President Donald Trump over the cost of medicine. Roche did boost U.S. prices for nine key drugs by an average of 3 percent on July 1, but said it would hold off additional increases as discussions with the Trump administration continue over a longer-term solution to containing healthcare costs.
Last week, Pfizer Inc. (NYSE: PFE) announced plans to restructure the company and plans to deter price increases for as long as possible, assuming that Trump makes some changes. Merck announced Thursday that it will lower the price of several medications while also limiting future price increases. The price of several medications will drop by 10 percent, including Prinivil, Remeron and Trusopt, according to Merck.
Like a growing number of its peers, Roche Holding AG pledged this week not to raise drug prices for the rest of the year. Roche gave the U.S. government its no-price-rises promise on July 11, the company said in a statement Friday. The health system also needs to focus on “long-term, system-wide solutions that lower costs,” Roche said.
European drugmakers Roche (ROG.S), Bayer (BAYGn.DE) and Merck KGaA (MRCG.DE) became the latest companies to freeze prices in the United States following criticism by the Trump administration of the cost of medicine. Roche, Bayer and Merck KGaA all said on Friday they would not seek to lift prices this year in the world's biggest drug market, following Novartis (NOVN.S), Pfizer (PFE.N) and U.S. drugmaker Merck (MRK.N) which had already announced similar moves.
Merck (MRK) announces a 60% cut in U.S. list prices for its hepatitis C drug, Zepatier. It will also lower the list price of some other drugs by 10%.
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after Honeywell reported second quarter adjusted earnings per share and revenue that beat Wall Street Expectations.
Michael Yee, Jefferies managing director, sheds light on Merck reducing prices on several drugs following Pfizer and Novartis announcing they will freeze price increases for the rest of the year.